Intracerebral Hemorrhage Clinical Trial
Official title:
Efficacy and Safety of Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is a critical disease of public health importance. Inflammatory mechanisms play a significant role in ICH. Thus, immune targets are supposed to be effective in protecting the neurological function of ICH. Fingolimod, a sphingosine-1-phosphate receptor regulator (FTY720), is an effective immunology modulator. It has been widely used in autoimmune disease and has also been testified effective in ICH who received conservative treatment. The present study aims to evaluate the efficiency and safety of fingolimod for ICH with minimal invasive treatment.
40 ICH patients who meet the inclusion criteria will be enrolled in the present study. All ICH patients will be screened. If meeting the including criteria, the investigators will contact the family, explain the study, and send a consent form for review. After obtaining written consent from the family, patients randomly assigned to the fingolimod group will be given 0.5mg/day oral fingolimod over a course of 3 consecutive days. Patients assigned to the control group will not receive fingolimod. All patients will receive minimal invasive puncture and drainage of hematoma. The investigators will evaluate the neurofunctional before and 30 days, 90 days and 180 days after oral fingolimod. CT scan will be performed at before, 7 and 14 days after oral fingolimod. 5ml intravenous blood for flow cytometry is also taken before and 1day, 3days, 7days after fingolimod use. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05089331 -
ROSE-Longitudinal Assessment With Neuroimaging
|
||
| Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
| Active, not recruiting |
NCT04522102 -
Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase
|
Phase 3 | |
| Terminated |
NCT04178746 -
PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
|
||
| Not yet recruiting |
NCT03956485 -
Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
|
||
| Enrolling by invitation |
NCT02920645 -
Multicenter Validation of the AVICH Score
|
N/A | |
| Recruiting |
NCT02625948 -
Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign
|
Phase 2 | |
| Completed |
NCT02478177 -
Addressing Real-world Anticoagulant Management Issues in Stroke
|
||
| Completed |
NCT01971359 -
Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study
|
N/A | |
| Completed |
NCT01261091 -
Early Tracheostomy in Ventilated Stroke Patients
|
N/A | |
| Terminated |
NCT00990509 -
Albumin for Intracerebral Hemorrhage Intervention
|
Phase 2 | |
| Completed |
NCT00716079 -
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
|
N/A | |
| Recruiting |
NCT00222625 -
rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets
|
Phase 2 | |
| Recruiting |
NCT05095857 -
The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
|
Phase 4 | |
| Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
| Recruiting |
NCT05492474 -
Cranial Ultrasound for Prehospital ICH Diagnosis
|
N/A | |
| Not yet recruiting |
NCT05502874 -
Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
|
||
| Recruiting |
NCT04604587 -
MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA
|
Phase 3 | |
| Recruiting |
NCT05504941 -
Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage
|
N/A | |
| Not yet recruiting |
NCT05066620 -
Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial
|
Phase 3 |